Finerenone as an add-on treatment to conventional therapies for the patients with diabetic kidney disease
Abstract
BACKGROUND: Finerenone has been shown to exert renoprotective effects in patients with diabetic kidney disease. However, the effects of finerenone on proteinuria and serum potassium levels in patients already receiving renin–angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors have not been fully elucidated. METHODS: A total of 47 patients with diabetic kidney disease already treated with angiotensin receptor blocker, angiotensin-converting-enzyme inhibitor or angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter 2 inhibitors and newly started treatment with finerenone were analyzed to identify predictors of finerenone-induced changes in proteinuria and serum potassium levels. RESULTS: After 57.8 ± 25.3 days of treatment with finerenone, urinary protein was significantly decreased from 2.61 ± 2.34 g/gCr to 2.29 ± 2.44 g/gCr and serum potassium was significantly elevated from 4.27 ± 0.36 mmol/L to 4.47 ± 0.42 mmol/L, respectively. There were no patients whose serum potassium levels reached 5.5 mmol/L. The amount of estimated sodium excretion was significantly correlated with the finerenone-induced changes in proteinuria and was the only significant predictive factor for the proteinuria-reducing effect of finerenone. Lower baseline serum potassium level was associated with a greater increase in serum potassium levels after finerenone administration. CONCLUSIONS: Proteinuria-lowering effect of finerenone may be influenced by the…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.